News

Under the agreement, Synaffix will be eligible for an upfront payment, milestone payments along with tiered royalties on net sales of resulting products. The company will also produce

Under the partnership, the companies will reveal the drug candidate’s mechanism of action as well as pharmacological characterisation. Salipro Biotech CEO Jens Frauenfeld said: “We are excited to

As per the agreement terms, Orbit will discover peptide leads specific to targets related to certain tumours by deploying its bead-based peptide display engine. Orbit Discovery CEO Dr

An engineered interleukin-2 (IL-2)-diphtheria toxin fusion protein, Lymphir is intended for relapsed or refractory CTCL patients following treatment with a minimum of one systemic therapy previously. As per

As per the agreement, Procaps will be responsible for activities related to registration, branding, marketing along with commercialisation throughout Latin America. Procaps submitted an initial set of eight

Under the agreement, Maruho will be responsible for the development and commercialisation of Qbrexza in South Korea, Brunei, Cambodia, Indonesia, Hong Kong, Macau, Vietnam, Malaysia, Philippines, Thailand, Myanmar,

The latest move comes after signing an exclusive licence agreement with HK inno.N in November 2020. The agreement granted sublicensing rights to UITC for developing, marketing, and manufacturing

The latest move is aimed at sharing the government’s objective to make obesity care accessible to patients with high unmet medical need. Through a controlled and limited launch,

The company will utilise proceeds from the round for further developing its technology platform to accelerate its lead programmes to clinical stage. The participants in the financing round